TABLE 5.

Immunogenicities of Fluad and Agrippala for HIV-1-seropositive subjects

ParameterVirus and vaccine group
A/H3/California/07/04A/H1/New Caledonia/20/99B/Shangai/361/02
FluadAgrippalFluadAgrippalFluadAgrippal
No. (%) of subjects who underwent seroconversion18 (54)22 (45)15 (45)20 (41)16 (48)23 (47)
No. (%) of subjects with seroprotection
    T023 (70)37 (75)26 (79)39 (79)28 (85)39 (79)
    T3031 (94)42 (86)31 (94)44 (90)31 (94)44 (90)
    T9028 (90)40 (83)28 (90)39 (81)28 (90)43 (90)
GMT
    T073.689.697.694.1102.9123.9
    T30398.9407535.4468.8481.9478.8
    T90198.8176.6297.9173.1210.9265.9
GMT ratio
    T30/T05.424.545.484.974.683.86
    T90/T02.71.973.051.842.052.15
Adjusted mean titer at T30 according to Beyer method4.32 ± 1.773.02 ± 1.964.53 ± 2.083.69 ± 2.383.8 ± 1.733.14 ± 1.97
Corresponding mean antibody titer at T3095.8840.58*115.664.769.544.2
  • a Samples were tested for 33 and 49 subjects, respectively, at T30 and for 31 and 48 subjects, respectively, at T90. *, P = 0.003.